A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
← catalyst calendarNCT07220954 · readout in 29 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Quotient Sciences.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
19actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-11 | actual | When the study began enrolling |
| Primary completion | 2026-09-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: AZD6234 Formulation 1 — also filed as AZD6234
- Drug: AZD6234 Formulation 2 (low concentration) — also filed as AZD6234
- Drug: AZD6234 Formulation 2 (high concentration) — also filed as AZD6234
- Drug: AZD6234 Formulation 3 — also filed as AZD6234
Primary outcomes
what the primary-completion date above is the date OFMaximum observed plasma concentration (Cmax)
measured Plasma sample collection from pre- dose to 30 days post final dose
Area under the concentration-time curve from time 0 to the time of the last measurable concentration (AUC0-t)
measured Plasma sample collection from pre- dose to 30 days post final dose
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)
measured Plasma sample collection from pre- dose to 30 days post final dose
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed